Stock Analysis on Net

Danaher Corp. (NYSE:DHR)

Analysis of Short-term (Operating) Activity Ratios 
Quarterly Data

Microsoft Excel

Short-term Activity Ratios (Summary)

Danaher Corp., short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021 Dec 31, 2020 Oct 2, 2020 Jul 3, 2020 Apr 3, 2020
Turnover Ratios
Inventory turnover 3.60 3.79 4.15 3.60 3.59 3.73 3.80 3.53 3.58 3.50 4.03 3.80 3.71 3.87 4.16 4.06 4.28 4.34 4.28
Receivables turnover 6.74 6.79 6.75 6.77 7.15 7.02 6.09 6.15 6.64 6.89 6.40 7.09 6.81 6.87 6.36 6.69 6.51 6.28 5.51
Payables turnover 5.62 5.57 5.52 6.04 5.84 5.88 5.58 5.63 5.82 5.68 5.45 5.61 5.00 5.04 4.48 5.20 5.54 5.29 4.79
Working capital turnover 5.71 8.27 8.85 8.73 8.10 3.60 4.22 2.18 3.08 3.81 4.20 5.00 5.43 5.91 8.40 7.98 3.12 3.45 3.48
Average No. Days
Average inventory processing period 101 96 88 101 102 98 96 104 102 104 91 96 98 94 88 90 85 84 85
Add: Average receivable collection period 54 54 54 54 51 52 60 59 55 53 57 51 54 53 57 55 56 58 66
Operating cycle 155 150 142 155 153 150 156 163 157 157 148 147 152 147 145 145 141 142 151
Less: Average payables payment period 65 66 66 60 63 62 65 65 63 64 67 65 73 72 82 70 66 69 76
Cash conversion cycle 90 84 76 95 90 88 91 98 94 93 81 82 79 75 63 75 75 73 75

Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).


The financial ratios demonstrate varying trends in the company's operational efficiency and working capital management over multiple quarters.

Inventory Turnover
The inventory turnover ratio showed a general decline from 4.28 in April 2020 to around 3.6-3.8 in recent quarters, indicating a slower rate of inventory movement. The ratio experienced fluctuations but mostly remained below the initial figure observed in early 2020, suggesting potential challenges in inventory management or changes in sales dynamics.
Receivables Turnover
Receivables turnover improved significantly from 5.51 in April 2020 to higher levels around 6.7 to 7.1 in several quarters, peaking at 7.15 in September 2024. This indicates enhanced efficiency in collecting receivables, reflecting better credit and collection policies or stronger cash inflows from customers.
Payables Turnover
Payables turnover displayed moderate variability. Starting around 4.79 in April 2020, it increased to approximately 5.5–6.0 from late 2021 onward. The upward trend suggests the company was paying its suppliers somewhat faster over time, which might imply improved supplier relationships or changes in payment terms.
Working Capital Turnover
The working capital turnover ratio showed significant volatility. After an initial figure of about 3.48, it spiked to nearly 8.4 in early 2021, then fluctuated downwards with some quarters reflecting sharp declines to around 2.18 by late 2022. Subsequently, the ratio surged again to levels above 8.0 in late 2024, before decreasing towards mid-2025. This volatility indicates varying efficiency in utilizing working capital, possibly due to changes in operational scale, inventory management, or receivables and payables dynamics.
Average Inventory Processing Period
The days inventory outstanding (DIO) gradually increased from 85 days in April 2020 to a peak near 104 days by early 2023, indicating longer inventory holding periods. There was some mild improvement toward late 2024, with values dropping closer to 88-96 days, although still elevated compared to earlier periods. This suggests increased capital tied in inventory over the years, with some recent improvements.
Average Receivable Collection Period
Receivable collection periods shortened from 66 days in April 2020 to a range mostly between 51 and 60 days in later quarters, demonstrating better collection efficiency. This aligns with the upward trend in receivables turnover, reflecting enhanced cash flow management related to account receivables.
Operating Cycle
The operating cycle length remained relatively stable, fluctuating between approximately 140 and 165 days across the periods. These fluctuations reflect the combined effects of changes in inventory processing and receivable collection periods, with no clear long-term improvement or deterioration pattern.
Average Payables Payment Period
The average payables payment period initially shortened from 76 days in April 2020 to the mid-60s in subsequent quarters, reaching as low as 60 days around mid-2024. This shortening indicates quicker payments to suppliers, impacting the cash outflows and working capital cycle.
Cash Conversion Cycle
The cash conversion cycle (CCC) showed considerable variation, starting around 75 days in early 2020, decreasing briefly to 63 days in early 2021, and then increasing to a peak around 98-95 days during 2022-2023. Toward 2024 and 2025, it again declined closer to 76-90 days. The fluctuating CCC indicates varying efficiency in converting investments in inventory and receivables back into cash, influenced by the movements in inventory, receivables, and payables periods.

Turnover Ratios


Average No. Days


Inventory Turnover

Danaher Corp., inventory turnover calculation (quarterly data)

Microsoft Excel
Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021 Dec 31, 2020 Oct 2, 2020 Jul 3, 2020 Apr 3, 2020
Selected Financial Data (US$ in millions)
Cost of sales 2,413 2,230 2,648 2,397 2,315 2,309 2,626 2,349 2,594 2,287 3,430 3,079 3,030 2,983 3,205 2,870 2,821 2,605 2,806 2,658 2,445 1,900
Inventories 2,689 2,532 2,330 2,678 2,671 2,645 2,594 3,024 3,183 3,383 3,110 3,236 3,257 3,072 2,767 2,737 2,547 2,424 2,292 2,422 2,593 2,575
Short-term Activity Ratio
Inventory turnover1 3.60 3.79 4.15 3.60 3.59 3.73 3.80 3.53 3.58 3.50 4.03 3.80 3.71 3.87 4.16 4.06 4.28 4.34 4.28
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc. 3.42 3.71 4.04 4.09 4.86 4.83 4.98 4.74 4.30 4.53 4.87 5.54 4.99 4.96 5.58 5.76 5.45 5.40 4.65
Amgen Inc. 1.88 1.88 1.84 1.75 1.42 1.14 0.89 1.41 1.38 1.31 1.30 1.34 1.40 1.48 1.58 1.53 1.53 1.53 1.58
Bristol-Myers Squibb Co. 5.18 5.28 5.46 3.57 3.72 3.70 4.02 4.33 4.39 3.93 4.33 4.77 4.59 4.55 4.74 4.85 5.01 5.61 5.68
Eli Lilly & Co. 0.84 0.96 1.11 1.05 1.16 1.17 1.23 1.40 1.37 1.36 1.54 1.86 1.79 1.93 1.88 1.79 1.80 1.68 1.38
Gilead Sciences Inc. 3.40 3.55 3.66 3.62 3.33 3.59 3.64 3.49 3.45 3.57 3.75 4.71 4.50 4.50 4.08 3.21 2.99 2.79 2.72
Johnson & Johnson 2.17 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77 2.87 2.86 2.91 2.86 3.04
Merck & Co. Inc. 2.25 2.43 2.49 2.45 2.39 2.42 2.54 2.63 2.66 2.72 2.95 3.10 3.06 2.74 2.29 2.73 2.79 2.40 2.45
Pfizer Inc. 1.52 1.60 1.65 1.66 2.05 2.15 2.45 2.65 2.31 3.07 3.82 3.62 3.66 3.67 3.40 2.78 1.80 1.28 1.08
Regeneron Pharmaceuticals Inc. 0.64 0.63 0.64 0.64 0.65 0.66 0.70 0.72 0.69 0.67 0.65 0.83 0.96 1.27 1.25 0.88 0.82 0.56 0.58
Thermo Fisher Scientific Inc. 4.57 4.82 5.06 4.62 4.83 4.93 5.06 4.83 4.64 4.62 4.60 4.29 4.03 3.87 3.88 3.90 4.03 4.01 4.02
Vertex Pharmaceuticals Inc. 1.06 1.14 1.27 1.37 1.53 1.65 1.71 1.71 1.90 2.06 2.35 2.69 2.70 2.83 2.56 2.58 2.52 2.56 2.62

Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).

1 Q2 2025 Calculation
Inventory turnover = (Cost of salesQ2 2025 + Cost of salesQ1 2025 + Cost of salesQ4 2024 + Cost of salesQ3 2024) ÷ Inventories
= (2,413 + 2,230 + 2,648 + 2,397) ÷ 2,689 = 3.60

2 Click competitor name to see calculations.


Cost of sales
The cost of sales exhibits a fluctuating pattern over the presented quarters. From April 2020 to December 2021, there is a general increasing trend, rising from $1,900 million to a peak of $3,205 million. This increase is somewhat erratic but mostly upward. Following December 2021, values show volatility, with both rises and declines through June 2025. Notably, substantial drops appear in March 2023 and March 2025, with corresponding recoveries in subsequent quarters. The pattern suggests variability potentially tied to operational factors or market conditions.
Inventories
Inventory levels have increased over the entire period but with more stability than cost of sales. Starting at $2,575 million in April 2020, inventories fluctuate modestly, reaching a high of $3,383 million in March 2023, then declining to a lower range around $2,532 million to $2,689 million by mid-2025. The inventory trend suggests an initial buildup which could be indicative of stockpiling or anticipated demand, followed by a controlled reduction in more recent periods.
Inventory turnover ratio
The inventory turnover ratio, available from late 2020 onwards, remains relatively stable but shows a slight downward trend overall. In the last quarters of 2020 and the first half of 2021, turnover ratios hover slightly above 4.0, indicating efficient inventory management. However, from late 2021 through mid-2025, the ratio mostly ranges between 3.5 and 3.8, with minor fluctuations. This decrease suggests that inventory is moving more slowly relative to sales, possibly reflecting changes in sales efficiency or inventory management practices.
General insights
Cost of sales increases alongside rising inventory levels initially, which is consistent with growth or increased operational scale. The subsequent decrease and fluctuation in cost of sales juxtaposed with a moderate decline in inventories and a slight drop in inventory turnover may signal adjustments in business operations or demand cycles. The overall trends imply that while inventory management remains steady, sales dynamics and associated costs experience more volatility, which may warrant closer monitoring to optimize profitability and capital use.

Receivables Turnover

Danaher Corp., receivables turnover calculation (quarterly data)

Microsoft Excel
Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021 Dec 31, 2020 Oct 2, 2020 Jul 3, 2020 Apr 3, 2020
Selected Financial Data (US$ in millions)
Sales 5,936 5,741 6,538 5,798 5,743 5,796 6,405 5,624 5,912 5,949 8,369 7,663 7,751 7,688 8,148 7,229 7,218 6,858 6,760 5,883 5,297 4,343
Trade accounts receivable, less allowance for doubtful accounts 3,564 3,506 3,537 3,507 3,298 3,379 3,922 4,201 4,199 4,313 4,918 4,409 4,527 4,407 4,631 4,194 4,103 3,949 4,045 3,496 3,378 3,433
Short-term Activity Ratio
Receivables turnover1 6.74 6.79 6.75 6.77 7.15 7.02 6.09 6.15 6.64 6.89 6.40 7.09 6.81 6.87 6.36 6.69 6.51 6.28 5.51
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc. 4.62 4.60 5.16 4.84 4.69 4.55 4.87 4.83 4.88 4.95 5.16 5.38 5.10 5.29 5.63 5.94 5.42 5.24 5.19
Amgen Inc. 3.85 4.03 4.72 4.26 4.26 4.16 3.70 4.17 4.34 4.34 4.46 4.60 4.62 4.81 4.96 5.11 5.39 5.41 5.36
Eli Lilly & Co. 3.76 4.07 4.09 3.97 3.53 4.56 3.75 3.93 3.93 3.68 4.14 4.35 4.57 4.64 4.24 4.69 4.58 4.56 4.18
Gilead Sciences Inc. 6.01 6.51 6.47 6.14 5.92 5.84 5.78 5.68 6.43 6.43 5.65 6.16 6.60 7.18 6.01 5.95 6.34 6.43 4.98
Johnson & Johnson 5.08 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08 6.14 6.13 6.00 5.64 6.08
Merck & Co. Inc. 5.37 5.92 6.24 5.55 5.37 5.40 5.81 5.71 5.29 5.56 6.27 6.22 5.93 5.49 5.28 5.56 6.00 5.65 6.11
Pfizer Inc. 5.29 5.27 5.55 4.18 4.93 5.09 5.33 6.25 7.66 7.57 9.16 6.21 6.68 6.99 7.08 5.81 5.23 4.70 5.28
Regeneron Pharmaceuticals Inc. 2.53 2.53 2.29 2.27 2.36 2.51 2.31 2.35 2.47 2.42 2.28 2.47 2.76 3.41 2.66 2.48 1.77 2.20 2.07
Thermo Fisher Scientific Inc. 5.03 5.07 5.23 5.13 5.33 5.36 5.21 5.19 5.43 5.53 5.53 5.76 5.53 5.21 4.92 7.03 6.99 6.46 5.61
Vertex Pharmaceuticals Inc. 6.03 6.15 6.85 6.07 6.24 5.68 6.31 6.27 6.11 5.95 6.19 6.28 6.26 6.15 6.66 6.48 7.19 6.56 7.01

Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).

1 Q2 2025 Calculation
Receivables turnover = (SalesQ2 2025 + SalesQ1 2025 + SalesQ4 2024 + SalesQ3 2024) ÷ Trade accounts receivable, less allowance for doubtful accounts
= (5,936 + 5,741 + 6,538 + 5,798) ÷ 3,564 = 6.74

2 Click competitor name to see calculations.


The sales figures exhibit a general upward trajectory from April 2020 through December 2021, increasing from 4,343 million USD to 8,148 million USD. Following this period, sales demonstrate noticeable fluctuations, with declines observed in early 2023 and again into mid-2024, before showing a mild recovery by mid-2025. This indicates periods of volatility after the initial growth phase.

The trade accounts receivable, net of doubtful accounts, maintain a somewhat stable but slightly fluctuating pattern over the entire period. The values range from 3,433 million USD in April 2020 to a peak near 4,918 million USD in December 2022, followed by a gradual decline to around 3,564 million USD by mid-2025. This suggests that while receivables increased alongside sales growth initially, cautious management or collection efforts may have contributed to the subsequent decline in receivables despite sales variability.

The receivables turnover ratio, which is available from the last quarter of 2020, reflects the efficiency of collection efforts. It displays an upward trend from 5.51 in October 2020 to a peak of approximately 7.15 in June 2024, signaling improving turnover and quicker collection cycles over time. There is minor variability, but the overall improvement suggests enhanced credit management and liquidity positions.

Sales Summary
Initial strong growth through 2021, reaching a peak over 8 billion USD, followed by volatility and some decline through early 2024, with partial recovery late in the analyzed period.
Trade Accounts Receivable
Increased in line with sales growth initially, peaking near the end of 2022, before a consistent downward adjustment in subsequent quarters, possibly reflecting tighter credit policies or improved collections.
Receivables Turnover
Consistent improvement in turnover ratio, indicating more efficient receivables management and faster cash conversion post-2020, peaking in mid-2024.

Payables Turnover

Danaher Corp., payables turnover calculation (quarterly data)

Microsoft Excel
Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021 Dec 31, 2020 Oct 2, 2020 Jul 3, 2020 Apr 3, 2020
Selected Financial Data (US$ in millions)
Cost of sales 2,413 2,230 2,648 2,397 2,315 2,309 2,626 2,349 2,594 2,287 3,430 3,079 3,030 2,983 3,205 2,870 2,821 2,605 2,806 2,658 2,445 1,900
Trade accounts payable 1,725 1,722 1,753 1,596 1,645 1,679 1,766 1,894 1,956 2,081 2,296 2,191 2,419 2,357 2,569 2,133 1,967 1,989 2,049 1,678 1,599 1,748
Short-term Activity Ratio
Payables turnover1 5.62 5.57 5.52 6.04 5.84 5.88 5.58 5.63 5.82 5.68 5.45 5.61 5.00 5.04 4.48 5.20 5.54 5.29 4.79
Benchmarks
Payables Turnover, Competitors2
Amgen Inc. 4.12 5.25 6.74 5.99 5.01 6.10 5.32 5.22 5.67 4.97 4.08 5.30 5.09 4.65 4.72 5.41 4.92 4.40 4.33
Bristol-Myers Squibb Co. 2.61 3.52 3.88 3.43 3.05 3.12 3.28 3.75 3.38 3.20 3.33 3.82 3.41 3.25 3.37 3.89 2.97 3.69 4.34
Eli Lilly & Co. 2.27 2.61 2.61 2.70 2.56 2.88 2.73 2.81 2.65 3.07 3.43 4.24 4.21 5.24 4.38 4.46 4.30 3.75 3.41
Gilead Sciences Inc. 10.65 8.47 7.50 7.49 12.57 10.69 11.81 9.90 9.06 8.99 6.25 11.22 11.89 11.43 9.36 9.18 8.70 8.71 5.42
Johnson & Johnson 3.07 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26 2.70 3.32 3.38 3.34 2.99
Merck & Co. Inc. 3.82 3.98 3.72 4.26 4.39 4.48 4.11 4.59 4.58 4.34 4.08 5.16 4.86 4.25 2.96 4.54 3.93 3.81 3.37
Pfizer Inc. 3.44 3.30 3.17 3.67 4.60 4.19 3.72 5.07 3.92 4.78 5.04 5.49 6.17 6.66 5.53 5.11 3.72 2.68 2.02
Regeneron Pharmaceuticals Inc. 2.83 2.84 2.50 3.87 3.32 2.67 2.99 3.43 3.14 2.69 2.65 3.74 4.00 5.39 4.32 4.23 3.42 2.23 2.36
Thermo Fisher Scientific Inc. 8.53 8.25 8.18 9.63 9.85 9.91 8.97 10.41 10.82 9.35 7.67 9.93 8.84 7.96 6.83 8.31 8.88 8.12 7.45
Vertex Pharmaceuticals Inc. 3.59 3.49 3.71 3.73 4.27 3.81 3.46 3.13 3.16 3.41 3.55 8.23 5.01 5.52 4.64 6.73 6.35 5.99 4.75

Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).

1 Q2 2025 Calculation
Payables turnover = (Cost of salesQ2 2025 + Cost of salesQ1 2025 + Cost of salesQ4 2024 + Cost of salesQ3 2024) ÷ Trade accounts payable
= (2,413 + 2,230 + 2,648 + 2,397) ÷ 1,725 = 5.62

2 Click competitor name to see calculations.


The data reveals several noteworthy trends over the observed quarterly periods. Cost of sales exhibits a fluctuating pattern, with notable peaks and troughs rather than a smooth trajectory. Beginning at $1,900 million in April 2020, cost of sales increased significantly, reaching a peak around the end of 2021 at about $3,205 million. This peak is followed by periods of decline and moderate recovery, with figures varying between approximately $2,230 million and $2,626 million from early 2023 through mid-2025.

Trade accounts payable demonstrate a generally declining trend over time, particularly from the fourth quarter of 2020 onward. Starting at around $1,748 million in April 2020, payables initially fluctuated mildly and experienced a peak near the end of 2021 at roughly $2,569 million. Subsequently, a downward movement is evident, with payables reduced to values closer to $1,600-$1,700 million by mid-2025.

The payables turnover ratio, available from the fourth quarter of 2020, generally trends upward with some oscillations. Starting near 4.79, the ratio increases steadily, crossing the 5.5 threshold multiple times from mid-2021 onward and reaching values around 6.0 in late 2024. This upward trend suggests faster turnover of payables relative to cost of sales over time, indicating improving efficiency in settling obligations or changes in payment terms.

Cost of sales
Shows significant volatility with pronounced increases through 2020 and 2021, peaking at over $3 billion at the end of 2021, followed by a gradual decline and stabilization in the $2.2-$2.6 billion range from 2023 onwards.
Trade accounts payable
Exhibits an initial increase leading to a peak at the end of 2021 (~$2.57 billion), then declines consistently towards mid-2025, reflecting possibly tighter control or reduced credit terms with suppliers.
Payables turnover ratio
Records a clear rising trend from Q4 2020 onward, moving from just below 5 to values consistently above 5.5 and approaching 6, denoting improved payment processing speed or more efficient management of payables relative to purchases.

Working Capital Turnover

Danaher Corp., working capital turnover calculation (quarterly data)

Microsoft Excel
Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021 Dec 31, 2020 Oct 2, 2020 Jul 3, 2020 Apr 3, 2020
Selected Financial Data (US$ in millions)
Current assets 10,999 9,525 9,497 10,060 9,609 14,372 13,937 21,205 17,461 16,532 15,883 14,250 13,229 12,670 11,648 10,776 15,392 14,012 13,802 12,541 12,344 11,143
Less: Current liabilities 6,792 6,645 6,798 7,339 6,701 7,778 8,274 9,367 8,404 8,730 8,389 8,002 7,556 7,547 8,140 7,257 6,825 6,824 7,402 6,038 5,600 8,466
Working capital 4,207 2,880 2,699 2,721 2,908 6,594 5,663 11,838 9,057 7,802 7,494 6,248 5,673 5,123 3,508 3,519 8,567 7,188 6,400 6,503 6,744 2,677
 
Sales 5,936 5,741 6,538 5,798 5,743 5,796 6,405 5,624 5,912 5,949 8,369 7,663 7,751 7,688 8,148 7,229 7,218 6,858 6,760 5,883 5,297 4,343
Short-term Activity Ratio
Working capital turnover1 5.71 8.27 8.85 8.73 8.10 3.60 4.22 2.18 3.08 3.81 4.20 5.00 5.43 5.91 8.40 7.98 3.12 3.45 3.48
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc. 130.12
Amgen Inc. 5.35 8.36 5.40 4.83 5.19 3.39 2.25 0.81 0.84 0.82 3.82 2.52 3.67 4.34 3.37 2.55 5.35 2.84 2.55
Bristol-Myers Squibb Co. 8.09 6.87 7.79 8.49 12.50 15.56 4.60 10.47 5.53 5.55 8.30 5.75 4.92 6.24 3.95 4.43 4.24 4.25 3.72
Eli Lilly & Co. 4.92 4.38 10.32 6.06 12.62 5.45 31.79 12.21 5.77 31.84 14.71 19.45 8.19 8.33 6.73 12.14 5.21 4.93
Gilead Sciences Inc. 8.14 6.27 3.99 9.22 17.98 26.58 5.61 6.74 84.15 9.14 8.42 8.56 6.87 6.68 8.54 7.25 7.09 7.06 5.30
Johnson & Johnson 284.99 6.10 15.94 58.86 22.29 10.35 11.81 9.37 14.06 23.02 4.88 5.02 5.57 5.95 5.97 5.93 7.26 9.44
Merck & Co. Inc. 5.77 6.19 6.19 5.86 5.14 9.68 9.29 6.69 8.86 5.63 5.16 5.58 6.39 6.09 7.62 6.51 6.97 84.97 109.83
Pfizer Inc. 10.68 6.64 8.64 5,036.00 29.17 1.62 2.03 6.89 11.00 3.83 5.05 6.10 4.78 4.29 4.21 3.60 4.58
Regeneron Pharmaceuticals Inc. 1.08 1.01 0.97 0.88 0.87 0.86 0.82 0.87 0.92 0.90 0.96 1.09 1.14 1.46 1.59 1.35 1.29 1.35 1.20
Thermo Fisher Scientific Inc. 3.64 4.20 4.87 4.61 3.96 4.38 4.05 4.86 7.40 10.13 5.46 5.40 6.03 6.13 5.87 2.30 3.10 3.36 2.76
Vertex Pharmaceuticals Inc. 1.82 1.78 1.83 1.82 1.92 1.07 0.93 0.87 0.90 0.93 0.85 0.90 0.93 0.97 1.02 1.03 1.01 0.97 0.99

Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).

1 Q2 2025 Calculation
Working capital turnover = (SalesQ2 2025 + SalesQ1 2025 + SalesQ4 2024 + SalesQ3 2024) ÷ Working capital
= (5,936 + 5,741 + 6,538 + 5,798) ÷ 4,207 = 5.71

2 Click competitor name to see calculations.


Working Capital
The working capital shows significant fluctuations over the periods analyzed. Initially, there is a marked increase from 2,677 million USD in April 2020 to a peak of 8,567 million USD in July 2021. Following this peak, a sharp decline is apparent by October 2021, with values dropping to 3,519 million USD. The working capital then demonstrates a generally upward trend, reaching a peak of 11,838 million USD in September 2023. However, subsequent quarters show a notable reduction, decreasing to 2,699 million USD by March 2025. This pattern indicates variability in the company's short-term liquidity position, with periods of both strengthening and weakening working capital.
Sales
Sales figures exhibit a general upward trajectory from April 2020 through December 2021, rising from 4,343 million USD to 8,148 million USD. Post-December 2021, sales experience more volatility, with a decline beginning in March 2023, reaching a low of 5,624 million USD in September 2023. Subsequent quarters show some recovery, although sales remain below the peak levels observed in late 2021. The fluctuations suggest impacts on revenue generation, possibly related to external market factors or internal operational changes.
Working Capital Turnover
The working capital turnover ratio presents notable variability throughout the periods for which data is available. Starting at 3.48 in December 2020, it increases sharply to 8.4 by December 2021, indicating improved efficiency in using working capital to generate sales during that time. After this peak, the ratio exhibits a declining trend, dropping to 2.18 by September 2023, which may suggest reduced efficiency or greater investment in working capital relative to sales. Following this dip, turnover ratios increase again, reaching values above 8.0 towards the end of the data series before a final decline to 5.71 in June 2025. The fluctuating ratio highlights changing dynamics in operational efficiency and working capital management over the analyzed quarters.

Average Inventory Processing Period

Danaher Corp., average inventory processing period calculation (quarterly data)

Microsoft Excel
Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021 Dec 31, 2020 Oct 2, 2020 Jul 3, 2020 Apr 3, 2020
Selected Financial Data
Inventory turnover 3.60 3.79 4.15 3.60 3.59 3.73 3.80 3.53 3.58 3.50 4.03 3.80 3.71 3.87 4.16 4.06 4.28 4.34 4.28
Short-term Activity Ratio (no. days)
Average inventory processing period1 101 96 88 101 102 98 96 104 102 104 91 96 98 94 88 90 85 84 85
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc. 107 98 90 89 75 75 73 77 85 81 75 66 73 74 65 63 67 68 79
Amgen Inc. 194 195 199 209 257 321 411 259 265 279 281 272 260 247 231 239 239 239 231
Bristol-Myers Squibb Co. 70 69 67 102 98 99 91 84 83 93 84 76 79 80 77 75 73 65 64
Eli Lilly & Co. 435 379 329 349 316 312 298 261 267 268 237 196 204 189 194 204 203 217 265
Gilead Sciences Inc. 108 103 100 101 110 102 100 105 106 102 97 78 81 81 89 114 122 131 134
Johnson & Johnson 168 163 165 169 166 158 154 149 164 155 147 136 136 132 127 128 125 128 120
Merck & Co. Inc. 162 150 147 149 153 151 144 139 137 134 124 118 119 133 159 134 131 152 149
Pfizer Inc. 239 229 222 219 178 170 149 138 158 119 95 101 100 99 107 131 203 284 338
Regeneron Pharmaceuticals Inc. 570 582 572 573 562 553 519 508 532 549 562 440 379 287 292 415 445 653 625
Thermo Fisher Scientific Inc. 80 76 72 79 76 74 72 76 79 79 79 85 91 94 94 94 91 91 91
Vertex Pharmaceuticals Inc. 345 320 287 267 238 222 214 213 192 177 156 136 135 129 143 142 145 142 139

Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).

1 Q2 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 3.60 = 101

2 Click competitor name to see calculations.


Inventory Turnover
The inventory turnover ratio shows a general declining trend over the observed quarterly periods starting from April 2, 2021 through June 27, 2025. Initially, the ratio was 4.28 and peaked slightly at 4.34 in July 2, 2021, then progressively decreased, reaching its lowest points around 3.5 to 3.6 during several quarters in 2023 and mid-2024. There is a notable rebound to 4.15 in March 28, 2025, followed by declines again toward the last reported quarters. This pattern suggests that the company is experiencing a slower rate of inventory turnover over time, with some intermittent improvements.
Average Inventory Processing Period
The average inventory processing period, expressed as the number of days inventory is held, demonstrates an inverse pattern relative to the inventory turnover ratio. Early in the dataset, around April 2, 2021, the inventory processing period stood at 85 days, then it gradually increased, peaking around 104 days in March 31, 2023 and again in September 29, 2023. After these peaks, the period shows some variability but remains elevated compared to the earlier values, with measurements mostly above 90 days. There is a temporary decline to 88 days by March 28, 2025 but it increases again shortly after. This overall increase in inventory days indicates that the company is holding inventory for longer durations, possibly reflecting slower movement of goods or changes in inventory management policies.
Relationship Between Metrics
The observed inverse relationship between inventory turnover and average inventory processing period is consistent and typical, where a lower turnover ratio correlates with a higher number of days inventory is held. The fluctuations in these two metrics suggest ongoing adjustments in either demand, supply chain efficiency, or inventory control practices. The modest recovery in turnover ratios toward the end of the period may indicate efforts to optimize inventory management, but persistent elevated inventory days imply that inventory clearance might still be less efficient than in earlier periods.

Average Receivable Collection Period

Danaher Corp., average receivable collection period calculation (quarterly data)

Microsoft Excel
Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021 Dec 31, 2020 Oct 2, 2020 Jul 3, 2020 Apr 3, 2020
Selected Financial Data
Receivables turnover 6.74 6.79 6.75 6.77 7.15 7.02 6.09 6.15 6.64 6.89 6.40 7.09 6.81 6.87 6.36 6.69 6.51 6.28 5.51
Short-term Activity Ratio (no. days)
Average receivable collection period1 54 54 54 54 51 52 60 59 55 53 57 51 54 53 57 55 56 58 66
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc. 79 79 71 75 78 80 75 76 75 74 71 68 72 69 65 61 67 70 70
Amgen Inc. 95 91 77 86 86 88 99 88 84 84 82 79 79 76 74 71 68 67 68
Eli Lilly & Co. 97 90 89 92 103 80 97 93 93 99 88 84 80 79 86 78 80 80 87
Gilead Sciences Inc. 61 56 56 59 62 62 63 64 57 57 65 59 55 51 61 61 58 57 73
Johnson & Johnson 72 65 61 67 67 64 64 62 68 65 62 60 62 60 59 60 61 65 60
Merck & Co. Inc. 68 62 58 66 68 68 63 64 69 66 58 59 62 66 69 66 61 65 60
Pfizer Inc. 69 69 66 87 74 72 69 58 48 48 40 59 55 52 52 63 70 78 69
Regeneron Pharmaceuticals Inc. 144 144 160 161 155 146 158 156 148 151 160 148 132 107 137 147 206 166 177
Thermo Fisher Scientific Inc. 73 72 70 71 68 68 70 70 67 66 66 63 66 70 74 52 52 56 65
Vertex Pharmaceuticals Inc. 61 59 53 60 58 64 58 58 60 61 59 58 58 59 55 56 51 56 52

Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).

1 Q2 2025 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 6.74 = 54

2 Click competitor name to see calculations.


Receivables Turnover
The receivables turnover ratio demonstrates an overall positive trend from the initial value of 5.51 in April 2021 to a peak around 7.15 in June 2024, indicating an improved efficiency in collecting receivables over time. The ratio fluctuates slightly but generally remains within a range of approximately 6.15 to 7.15. This suggests a relatively stable ability to convert receivables into cash promptly, with some periods of enhanced collection speed particularly evident between mid-2022 and mid-2024.
Average Receivable Collection Period
Corresponding to the turnover pattern, the average receivable collection period in days shows a decrease from 66 days in April 2021 to a low near 51 days in late 2022 and mid-2024. This reduction reflects shorter outstanding receivables and quicker collection times. Despite some minor variations, the collection period remains mostly within a band of 51 to 60 days. The overall downward movement suggests improvements in credit and collection policies or operational efficiencies that reduce the time needed to collect outstanding receivables.
Correlation and Insights
There is an inverse relationship evident between the receivables turnover ratio and the average collection period, as expected theoretically. Higher turnover ratios coincide with shorter collection periods, signaling effective receivables management. The data imply sustained improvements in the company's credit control processes over the reported periods, resulting in faster conversion of receivables to cash. These trends contribute positively to liquidity management and operational cash flow.

Operating Cycle

Danaher Corp., operating cycle calculation (quarterly data)

No. days

Microsoft Excel
Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021 Dec 31, 2020 Oct 2, 2020 Jul 3, 2020 Apr 3, 2020
Selected Financial Data
Average inventory processing period 101 96 88 101 102 98 96 104 102 104 91 96 98 94 88 90 85 84 85
Average receivable collection period 54 54 54 54 51 52 60 59 55 53 57 51 54 53 57 55 56 58 66
Short-term Activity Ratio
Operating cycle1 155 150 142 155 153 150 156 163 157 157 148 147 152 147 145 145 141 142 151
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc. 186 177 161 164 153 155 148 153 160 155 146 134 145 143 130 124 134 138 149
Amgen Inc. 289 286 276 295 343 409 510 347 349 363 363 351 339 323 305 310 307 306 299
Eli Lilly & Co. 532 469 418 441 419 392 395 354 360 367 325 280 284 268 280 282 283 297 352
Gilead Sciences Inc. 169 159 156 160 172 164 163 169 163 159 162 137 136 132 150 175 180 188 207
Johnson & Johnson 240 228 226 236 233 222 218 211 232 220 209 196 198 192 186 188 186 193 180
Merck & Co. Inc. 230 212 205 215 221 219 207 203 206 200 182 177 181 199 228 200 192 217 209
Pfizer Inc. 308 298 288 306 252 242 218 196 206 167 135 160 155 151 159 194 273 362 407
Regeneron Pharmaceuticals Inc. 714 726 732 734 717 699 677 664 680 700 722 588 511 394 429 562 651 819 802
Thermo Fisher Scientific Inc. 153 148 142 150 144 142 142 146 146 145 145 148 157 164 168 146 143 147 156
Vertex Pharmaceuticals Inc. 406 379 340 327 296 286 272 271 252 238 215 194 193 188 198 198 196 198 191

Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).

1 Q2 2025 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 101 + 54 = 155

2 Click competitor name to see calculations.


The analysis of the provided quarterly financial data reveals notable trends in the inventory processing period, receivable collection period, and operating cycle over time.

Average Inventory Processing Period
The inventory processing period exhibits fluctuations throughout the observed quarters. Starting from the available data in the second quarter of 2021 at 85 days, it remains relatively stable around the mid-80s to low 90s for several quarters. There is a noticeable increase reaching a peak of 104 days in the first quarter of 2023 and again in the third quarter of 2023. Following these peaks, the period slightly decreases and fluctuates around the mid-90s to low 100s range toward the most recent quarters. Overall, this indicates some variability with an upward trend in 2023, followed by moderate stabilization.
Average Receivable Collection Period
The receivable collection period demonstrates a trend of gradual improvement (shortening) from approximately 66 days in the second quarter of 2021 to mid-50s days in late 2021 and early 2022, implying enhanced efficiency in collecting receivables. A brief increase occurs in late 2022 and into 2023, peaking near 60 days, before returning to the low 50s range in more recent quarters. Despite occasional upward fluctuations, the overall trend suggests a positive trajectory towards quicker receivable collection after mid-2021, with some volatility in 2023.
Operating Cycle
The operating cycle, defined as the sum of inventory processing and receivable collection periods, reflects similar dynamics. From the early data points in mid-2021 at approximately 151 days, the cycle experiences mild variability with values hovering between 140 and 160 days. A gradual increase is observed through 2022 and into early 2023, reaching a peak of 163 days in the first quarter of 2023, coinciding with the inventory processing period peak. Subsequently, the cycle shows signs of slight decline toward mid-2023 but remains elevated compared to earlier periods. This pattern indicates some lengthening in operational duration, influenced primarily by the increased inventory processing period.

In summary, the data reflect moderate fluctuations in inventory management efficiency, as indicated by the inventory processing period, with notable increases during 2023. The receivable collection period tends toward improved efficiency, with shorter durations after mid-2021, although it experienced some volatility in 2023. Consequently, the operating cycle shows corresponding variation, shaped predominantly by inventory trends, suggesting the need for ongoing focus on inventory turnover to optimize overall operational efficiency.


Average Payables Payment Period

Danaher Corp., average payables payment period calculation (quarterly data)

Microsoft Excel
Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021 Dec 31, 2020 Oct 2, 2020 Jul 3, 2020 Apr 3, 2020
Selected Financial Data
Payables turnover 5.62 5.57 5.52 6.04 5.84 5.88 5.58 5.63 5.82 5.68 5.45 5.61 5.00 5.04 4.48 5.20 5.54 5.29 4.79
Short-term Activity Ratio (no. days)
Average payables payment period1 65 66 66 60 63 62 65 65 63 64 67 65 73 72 82 70 66 69 76
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Amgen Inc. 89 70 54 61 73 60 69 70 64 73 90 69 72 78 77 67 74 83 84
Bristol-Myers Squibb Co. 140 104 94 106 120 117 111 97 108 114 109 96 107 112 108 94 123 99 84
Eli Lilly & Co. 161 140 140 135 142 127 134 130 138 119 106 86 87 70 83 82 85 97 107
Gilead Sciences Inc. 34 43 49 49 29 34 31 37 40 41 58 33 31 32 39 40 42 42 67
Johnson & Johnson 119 123 137 120 121 113 132 111 133 120 137 118 116 112 135 110 108 109 122
Merck & Co. Inc. 95 92 98 86 83 81 89 80 80 84 89 71 75 86 123 80 93 96 108
Pfizer Inc. 106 110 115 99 79 87 98 72 93 76 72 66 59 55 66 71 98 136 181
Regeneron Pharmaceuticals Inc. 129 129 146 94 110 137 122 106 116 136 138 98 91 68 84 86 107 164 155
Thermo Fisher Scientific Inc. 43 44 45 38 37 37 41 35 34 39 48 37 41 46 53 44 41 45 49
Vertex Pharmaceuticals Inc. 102 105 98 98 85 96 106 117 115 107 103 44 73 66 79 54 57 61 77

Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).

1 Q2 2025 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 5.62 = 65

2 Click competitor name to see calculations.


Payables Turnover Ratio
The payables turnover ratio exhibits a fluctuating trend over the analyzed periods, beginning at 4.79 and increasing to a peak of 6.04 before slightly decreasing toward the end of the timeline. Notably, there was a decline from 5.54 to 5.2 during late 2020, followed by an overall upward movement with minor oscillations. The highest ratio recorded is 6.04, indicating a faster rate of accounts payable turnover at that point compared to other periods.
Average Payables Payment Period
The average payables payment period, measured in number of days, shows an inverse pattern relative to the payables turnover ratio. Initially recorded at 76 days, it decreases steadily to a low of 60 days, which corresponds with the periods of higher payables turnover ratio. There is some variability with occasional increases, such as a rise to 82 days early in 2022, but the general trend indicates improved efficiency in settling payables over time, with the payment period shortening overall.
General Insights
Across the reported quarters, the data suggest an overall improvement in the management of accounts payable. The increasing payables turnover coupled with the decreasing average payment period signifies a tendency toward quicker payments to suppliers. The fluctuations in both metrics, however, imply some variability in payment practices, possibly influenced by operational or market conditions.

Cash Conversion Cycle

Danaher Corp., cash conversion cycle calculation (quarterly data)

No. days

Microsoft Excel
Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021 Dec 31, 2020 Oct 2, 2020 Jul 3, 2020 Apr 3, 2020
Selected Financial Data
Average inventory processing period 101 96 88 101 102 98 96 104 102 104 91 96 98 94 88 90 85 84 85
Average receivable collection period 54 54 54 54 51 52 60 59 55 53 57 51 54 53 57 55 56 58 66
Average payables payment period 65 66 66 60 63 62 65 65 63 64 67 65 73 72 82 70 66 69 76
Short-term Activity Ratio
Cash conversion cycle1 90 84 76 95 90 88 91 98 94 93 81 82 79 75 63 75 75 73 75
Benchmarks
Cash Conversion Cycle, Competitors2
Amgen Inc. 200 216 222 234 270 349 441 277 285 290 273 282 267 245 228 243 233 223 215
Eli Lilly & Co. 371 329 278 306 277 265 261 224 222 248 219 194 197 198 197 200 198 200 245
Gilead Sciences Inc. 135 116 107 111 143 130 132 132 123 118 104 104 105 100 111 135 138 146 140
Johnson & Johnson 121 105 89 116 112 109 86 100 99 100 72 78 82 80 51 78 78 84 58
Merck & Co. Inc. 135 120 107 129 138 138 118 123 126 116 93 106 106 113 105 120 99 121 101
Pfizer Inc. 202 188 173 207 173 155 120 124 113 91 63 94 96 96 93 123 175 226 226
Regeneron Pharmaceuticals Inc. 585 597 586 640 607 562 555 558 564 564 584 490 420 326 345 476 544 655 647
Thermo Fisher Scientific Inc. 110 104 97 112 107 105 101 111 112 106 97 111 116 118 115 102 102 102 107
Vertex Pharmaceuticals Inc. 304 274 242 229 211 190 166 154 137 131 112 150 120 122 119 144 139 137 114

Based on: 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).

1 Q2 2025 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 101 + 5465 = 90

2 Click competitor name to see calculations.


Inventory Processing Period
The average inventory processing period shows an increasing trend over the observed quarters, with a starting value near 85 days in early 2021 and peaking at 104 days in several quarters during 2023. The period fluctuates marginally but generally remains elevated around the 96 to 104 days mark towards the end of the timeline. This indicates a tendency for inventory to be held longer before processing, which could imply increasing inventory levels or slower turnover.
Receivable Collection Period
The average receivable collection period demonstrates a gradual decline from 66 days at the beginning of 2021 to a lower range around 51 to 54 days in the latter quarters. Notably, occasional rises to 59 and 60 days are observed near late 2022 to early 2023. Despite these short-term increases, the overall decline suggests improved efficiency in collecting receivables, shortening the time customers take to pay.
Payables Payment Period
The average payables payment period shows variability without a clear directional trend. It decreases from a high of 76 days at the beginning of 2021 to lows near 60 days in mid-2024, but also experiences intermittent increases up to 82 days in early 2022. The payment period stabilizes around the mid-60 day mark towards the end of the timeline, indicating fluctuating yet relatively consistent supplier payment timing.
Cash Conversion Cycle
The cash conversion cycle exhibits notable fluctuations, with initial values around 75 days rising to a peak of 98 days in late 2023. After peaking, the cycle declines to approximately 76 days by early 2025, before slightly increasing again towards 90 days. The extension of the cash conversion cycle in the middle periods reflects a longer duration for the company to convert its investments in inventory and other resources into cash flows from sales, possibly linked to the rising inventory processing and variable payment periods.
Summary of Overall Trends
Over the observed periods, there is a discernible increase in inventory holding times combined with an improved receivables collection period, suggesting some operational efficiency in receivables but challenges or strategic changes affecting inventory turnover. Payables period does not follow a consistent pattern, reflecting possible strategic supplier payment management or external supplier factors. The cash conversion cycle's volatility mainly mirrors these movements, showing a longer cycle during the mid-term quarters and a partial recovery thereafter, indicating fluctuations in working capital efficiency.